Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hormone Receptor Positive Malignant Neoplasm of Breast Clear all
Completed Phase 2 Interventional Results available

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

NCT01560416
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, Ganetespib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
5
States / cities
Boston, Massachusetts • Concord, New Hampshire • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jul 22, 2026, 12:56 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
ARV-471, Fulvestrant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
87
States / cities
Encinitas, California • Fountain Valley, California • Fresno, California + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jul 22, 2026, 12:56 AM EDT
Recruiting Not applicable Interventional

Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer

NCT04030507
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Inflammatory Breast Cancer, Metastatic Breast Cancer
Interventions
MRI
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 22, 2026, 12:56 AM EDT
Active, not recruiting No phase listed Observational

Comparison of the Breast Tumor Microenvironment

NCT03165487
View directory record Official record
Conditions
Triple Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions
Breast tissue collection, Blood sample collection
Other
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

NCT01177397
View directory record Official record
Conditions
Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Neuroendocrine Tumors of Non-Pancreatic Origin, Hormone Receptor-Positive Breast Cancer
Interventions
CC-223
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Jul 22, 2026, 12:56 AM EDT
Recruiting Phase 1 Interventional

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

NCT07137416
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic HER2-Low Breast Carcinoma, Metastatic HER2-Positive Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma, Unresectable HER2-Low Breast Carcinoma, Unresectable HER2-Positive Breast Carcinoma, Unresectable Hormone Receptor-Positive Breast Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan, Pidnarulex, Radiologic Imaging Procedure, Trastuzumab Deruxtecan
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 22, 2026, 12:56 AM EDT
Terminated Phase 2 Interventional Results available

Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer

NCT04720664
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Breast Carcinoma
Interventions
SM-88
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Jul 22, 2026, 12:56 AM EDT
Terminated Phase 3 Interventional

Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC

NCT03326674
View directory record Official record
Conditions
Breast Cancer
Interventions
Tesetaxel and Capecitabine, Capecitabine
Drug
Lead sponsor
Odonate Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
90
States / cities
Chandler, Arizona • Goodyear, Arizona • Tucson, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Jul 22, 2026, 12:56 AM EDT
Recruiting Phase 1 Interventional

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT05283330
View directory record Official record
Conditions
Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Glioblastoma, Nonsmall Cell Lung Cancer
Interventions
²¹²Pb-DOTAM-GRPR1
Drug
Lead sponsor
Orano Med Theranostics, SAS
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
8
States / cities
Chicago, Illinois • Iowa City, Iowa • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Phase 1 Interventional

Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer

NCT03088527
View directory record Official record
Conditions
Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions
RAD140
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
New Haven, Connecticut • Boston, Massachusetts • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Jul 22, 2026, 12:56 AM EDT
Completed No phase listed Observational

PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score

NCT01617954
View directory record Official record
Conditions
Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions
MammaPrint
Device
Lead sponsor
Agendia
Industry
Eligibility
18 Years to 90 Years · Female only
Enrollment
820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
53
States / cities
Phoenix, Arizona • Burbank, California • Palm Springs, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Phase 1 Interventional

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

NCT02152943
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive, HER2/Neu Positive, Postmenopausal, Premenopausal, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Refractory Breast Carcinoma, Refractory Hormone Receptor Positive Breast Carcinoma, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Everolimus, Laboratory Biomarker Analysis, Letrozole, Trastuzumab
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jul 22, 2026, 12:56 AM EDT
Terminated Phase 1 Interventional

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

NCT06878248
View directory record Official record
Conditions
Breast Cancer Metastatic, Locally Advanced Breast Cancer (LABC), Malignant Neoplasm of Breast, Triple Negative Breast Cancer (TNBC), Hormone Receptor-Positive Breast Cancer, HER2 + Breast Cancer
Interventions
Two Component Product CLBR001 + ABBV-461
Biological
Lead sponsor
Calibr, a division of Scripps Research
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Augusta, Georgia • Indianapolis, Indiana • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Phase 1 Interventional

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

NCT03854903
View directory record Official record
Conditions
Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer
Interventions
Palbociclib, Bosutinib, Fulvestrant
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Jul 22, 2026, 12:56 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

NCT05104866
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd, Capecitabine, Gemcitabine, Eribulin, Vinorelbine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
14
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 22, 2026, 12:56 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

NCT03845166
View directory record Official record
Conditions
Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer
Interventions
XL092, Atezolizumab, Avelumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
40
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Jul 22, 2026, 12:56 AM EDT
Withdrawn Phase 2 Interventional

Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer

NCT00615524
View directory record Official record
Conditions
Hormone-receptor Positive Breast Cancer
Interventions
exemestane and pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Jul 22, 2026, 12:56 AM EDT
Recruiting Phase 3 Interventional

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

NCT07205822
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Largo, Florida • Fort Wayne, Indiana • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 22, 2026, 12:56 AM EDT
Recruiting Phase 1 Interventional

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

NCT06120283
View directory record Official record
Conditions
Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer
Interventions
BGB-43395, Fulvestrant, Letrozole, Elacestrant, Anti-Diarrheal Agent
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Denver, Colorado • Lake Mary, Florida • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 22, 2026, 12:56 AM EDT
Recruiting Phase 1Phase 2 Interventional

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

NCT05735080
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer
Interventions
INX-315, Fulvestrant, Abemaciclib
Drug
Lead sponsor
Incyclix Bio
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
15
States / cities
Orlando, Florida • Atlanta, Georgia • Augusta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Phase 1 Interventional Results available

BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer

NCT01870505
View directory record Official record
Conditions
Metastatic or Locally-advanced Unresectable Breast Cancer
Interventions
BYL719, Letrozole, Exemestane
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Jul 22, 2026, 12:56 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

NCT04561362
View directory record Official record
Conditions
Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms, Ovarian Neoplasm, Advanced Solid Tumor
Interventions
BT8009, Pembrolizumab
Drug
Lead sponsor
BicycleTx Limited
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Denver, Colorado • Ocala, Florida • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jul 22, 2026, 12:56 AM EDT
Active, not recruiting Phase 3 Interventional

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

NCT04711252
View directory record Official record
Conditions
ER-Positive HER2-Negative Breast Cancer
Interventions
AZD9833, Anastrozole, Anastrozole placebo, AZD9833 placebo, Palbociclib, Luteinizing hormone-releasing hormone (LHRH) agonist
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
30
States / cities
Mobile, Alabama • Springdale, Arkansas • Harbor City, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 22, 2026, 12:56 AM EDT
Recruiting Phase 4 Interventional

A Study of Revaree Plus in People With Breast Cancer

NCT07042581
View directory record Official record
Conditions
Breast Cancer, Stage 0 Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Stage 0 Breast Carcinoma, Stage II Breast Carcinoma, Stage III Breast Carcinoma, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions
Revaree Plus
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 22, 2026, 12:56 AM EDT